October 2013. XCellAssay was founded by a group of colleagues with an enthusiasm for innovative solutions to today's environmental and clinical problems. The studies were based upon published studies conducted in the UCSF (University of California San Francisco) laboratory of XCellAssay co-founder, Dr. Fred Schaufele. That research led to the development of an elegant, innovative detection technology that overcomes deficiencies in hormone and drug monitoring by current technologies.

April 2014. 
XCellAssay begins laboratory operations.

April 2014. University of California files for patent on enabling BioAssay technology (Patent allowed Feb 2019).

March 2015. University of California signs a QuickStart agreement with 
XCellAssay to negotiate exclusively with XCellAssay for a license or option to the University of California IP. This option remains in effect. 

March 2015. 
XCellAssay receives Freedom to Operate report compiled by law students working with XCellAssay through the UC Hastings Startup Legal Garage.

XCellAssay collaborates with clinicians on a number of studies validating the utility of BioAssay measurements. Those studies have shown that the pan-hormone/anti-hormone assessments provided by the BioAssays improve diagnosis and treatment monitoring compared to the more limited diagnostic tools currently available to patients and their physicians.

August 2017. 
XCellAssay initiates studies supported by a research grant from the Partnership for Clean Competition for the project "Androgen monitoring of amateur and youth athletes". This project applies the BioAssay technology for the detection of hormonal imbalances arising from the use of performance enhancing drugs.

2018-2019. XCellAssay develops BioAssay tools to evaluate if excess androgens originate naturally from within the individual's body or 'exogenously' from outside chemicals absorbed by or consumed by the individual.